Efficacy, Safety of Nivolumab Plus Cabozantinib Versus Sunitinib for Patients With Advanced Renal Cell Carcinoma

Conference|ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.

Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, on her presentation at the 2021 ASCO Annual Meeting on nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).

During the discussion, Apolo detailed some of the findings of the phase 3 trial around the efficacy and safety of nivolumab plus cabozantinib versus sunitinib for patients with aRCC.